IN VITRO ANTIBACTERIAL ACTIVITY OF DL-8280 AND ITS THERAPEUTIC EFFICACY ON RESPIRATORY TRACT INFECTIONS

• Published in: CHEMOTHERAPY Vol. 32; no. Supplement1; pp. 178 - 184
• Main Authors: AONUMA, SEIICHI, ONUMA, KIKUO, WATANABE, AKIRA, SASAKI, MASAKO, OIZUMI, KOTARO, KONNO, KIYOSHI, NAGAI, KOSAKU
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1984
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.32.Supplement1_178

Recently, a new oral antibiotic agent, structurally related to nalidixic acid, was synthesized in laboratory of Daiichi Seiyaku Co., Ltd., in Japan. It was shown that this new agent possessed a broad antimicrobial spectrum covering gram-negative cocci and gram-negative bacilli. Minimal inhibitory concentrations (MICs) of the agent against each 20 clinical isolates of S. aureus, E. coli, K. pneumoniae, S. marcescens, E. cloacae and P. aeruginosa were determined by use of Dynatech MIC 2000 system. The growth of all the tested strains of S. aureus was inhibited at 0.39 μg/ml of the agent. At a concentration of 0.78 μg/ml, this agent inhibited 95, 90 and 85 per cent of the strains of S. marcescens, E. coli and E. cloacae, respectively. A concentration of 1.56 μg/ml was required to inhibit 80 per cent of the strains of P. aeruginosa. Sixteen patients suffering from respiratory tract infections received orally 300 to 600 mg of the drug a day. 3 patients who visited only once at the start of the treatment was omitted from the evaluation of therapeutic efficacy of the drug. In remaining 13 patients, 2 showed an excellent response, 9 a good response and 2 a fair response. No undesirable symptoms and signs due to administration of the drug was observed. No abnormality in laboratory findings was noted during and after the treatment with the drug.